In light of this, this study aimed to assess the adherence of physicians to ADA recommendations in the prescription of SGLT2 inhibitors and GLP1-RAs - medications that offer proven cardiovascular benefits - to patients with type 2 diabetes and established ASCVD or those with indications of high ASCVD risk, as well as in the prescription of SGLT2 inhibitors to heart failure patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.